Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.